Multicentre field evaluation of Xpert MTB/XDR in sub-Saharan Africa.
Massou F, Diarra B, Ba Diallo A, Bah KS, Vuchas C, Neh A, Sander M, Adebiyi EO, Aderemi BO, Agbla SC, Floyd S, Kaswa MK, Aloni M, Sissy M, Ushizimpumu B, Niyigena EB, Ngabonziza JCS, Abebe G, Tadesse M, Bah B, Camara L, Gaye Diallo A, Camara M, Diallo F, Togo ACG, Ferré A, Badalato N, Penn-Nicholson A, Schumacher SG, Odjougbele ST, Houeto S, Mulders W, Frissette K, Kebede W, El Tayeb O, Merle CS, de Jong BC, Supply P, Affolabi D, Rigouts L.
Treating drug resistant (DR) tuberculosis (TB) requires complex regimens combining multiple second-line drugs. Owing to their potent bactericidal properties, fluoroquinolones (FQ) are recommended for inclusion in regimens for DR-TB regimens, whether short (all-oral 9-month or all-oral 6-month) or longer treatment regimens, as well as in the 6-month regimen for rifampicin-susceptible (RS) yet isoniazid (INH)-resistant TB treatment.
